Table 1 Administration of Abs against DENV NS1 in different mouse models

NS1 polyclonal antisera

500 l (i.p.) 24 h prior to challenge

100 LD50 of DENV2 (NGC) /i.c.

BALB/c

100% survival

[113]

Monoclonal ascitic fluid

1-10 mg/mouse (i.p.) 24 h prior to challenge

100 LD50 of DENV2 (NGC) /i.c.

BALB/c

50-93% survival

[113]

NS1 polyclonal antisera

300 μl (i.p.) cotreatment

NS1 (10 mg/kg) + 1×106 PFU of DENV2 (adapted strain D220)/ i.v.

Ifnar−/−C57BL/6

100% survival

[38]

Anti-NS1 mAb (1H7.4)

200 μg (i.p.) cotreatment

NS1 (10 mg/kg) +1×106 PFU of DENV2 (adapted strain D220)/ i.v.

Ifnar−/−C57BL/6

100% survival

[38]

Anti-DJ NS1 and anti-ΔC^a NS1 polyclonal Abs

50-150 μg/mouse (i.p.) 24 h after challenge

9×107 PFU of DENV2 (16681)/i.d.; 1×107 PFU of DENV2 (454009A)/i.v.

C3H/HeN

Reduce hemorrhage; rescue partial bleeding prolonged

[96, 114]

Anti-NS1 mAb (33D2)

100 μg/mouse (i.p.)

24 h after challenge

2×108 PFU of DENV1-4/i.d.; 4×107

PFU of DENV2 (454009A)/i.v.

C3H/HeN; STAT1-/-C57BL/6

80% survival; reduce viremia and NS1 antigenemia; reduce hemorrhage; rescue partial bleeding prolong

[97]

Anti-DJ^b NS1 polyclonal Abs

Two doses of 150 μg/mouse (i.p.) 24 and 48 h after challenge

1×107 PFU/mouse

DENV2 (16681)/i.d.

STAT1-/-

C57BL/6

Reduce mast cell degranulation, macrophage infiltration and chemokine production

[115]

Anti-NS1 mAb (2E8)

One dose of 50-150 μg/mouse (i.p.) either 1, 3, or 4 days after challenge

1×107 PFU/mouse

STAT1-/-C57BL/6

Reduce viremia and NS1 antigenemia; rescue partial bleeding prolong

[114]